دورية أكاديمية
Evaluation of antioxidant, anti-inflammatory, anticancer activities and molecular docking of Moringa oleifera seed oil extract against experimental model of Ehrlich ascites carcinoma in Swiss female albino mice.
| العنوان: | Evaluation of antioxidant, anti-inflammatory, anticancer activities and molecular docking of Moringa oleifera seed oil extract against experimental model of Ehrlich ascites carcinoma in Swiss female albino mice. |
|---|---|
| المؤلفون: | Aldayel TS; Department of Health Sciences, Clinical Nutrition, College of Health and Rehabilitation Sciences, Princess Nourah bint Abdulrahman University, Riyadh, 11671, Saudi Arabia., Gad El Hak HN; Department of Zoology, Faculty of Science, Suez Canal University, Ismailia, Egypt. heba_ahmed@science.suez.edu.eg., Nafie MS; Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, 41522, Egypt., Saad R; Department of Clinical Pathology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt., Abdelrazek HMA; Department of Physiology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt., Kilany OE; Department of Clinical Pathology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. |
| المصدر: | BMC complementary medicine and therapies [BMC Complement Med Ther] 2023 Dec 14; Vol. 23 (1), pp. 457. Date of Electronic Publication: 2023 Dec 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101761232 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-7671 (Electronic) Linking ISSN: 26627671 NLM ISO Abbreviation: BMC Complement Med Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2020]- |
| مواضيع طبية MeSH: | Moringa oleifera* , Carcinoma, Ehrlich Tumor*/drug therapy , Carcinoma, Ehrlich Tumor*/pathology, Female ; Mice ; Animals ; Antioxidants/chemistry ; Molecular Docking Simulation ; Ascites ; Quercetin ; Plant Extracts/chemistry ; Anti-Inflammatory Agents/therapeutic use ; Plant Oils |
| مستخلص: | The current research intended to evaluate the antitumor properties of Moringa oleifera oil extract (MOE). Fifty-six female Swiss albino mice were employed in this study. Animals were assigned into four groups: control (C) group, moringa oil extract (MOE) group administered (500 mg/kg b. wt) MOE daily via gavage, Ehrlich ascites carcinoma (EAC) group and EAC group administered daily with (500 mg/kg b.wt) MOE for two weeks (EAC/MOE). The results showed that MOE significantly ameliorated the EAC increase in body weight and reduced the EAC cell viability. In addition, they upgraded the levels of hepatic and renal functions, inflammatory cytokines, oxidative stress markers and EAC-induced hepatic and renal histopathological changes. Treatment of EAC with MOE induced antitumor, anti-inflammatory and antioxidant effects and normalized most of the tested parameters besides the histopathological alterations in both renal and hepatic tissues. HPLC for the MOE identified Cinnamic acid, Ellagic acid, Quercetin, Gallic acid, Vanillin and Hesperidin as major compounds. The molecular docking study highlighted the virtual binding of the identified compounds inside the GSH and SOD proteins, especially for Quercetin which exhibited promising binding affinity with good interactive binding mode with the key amino acids. These results demonstrate that the antitumor constituents of MOE against EAC induced oxidative stress and inflammation by preventing oxidative damage and controlling EAC increase. (© 2023. The Author(s).) |
| References: | Biomed Pharmacother. 2003 May-Jun;57(3-4):145-55. (PMID: 12818476) Clin Chest Med. 2018 Mar;39(1):79-97. (PMID: 29433727) PLoS One. 2012;7(10):e46858. (PMID: 23056490) Am J Phys Anthropol. 2009 Jun;139(2):109-25. (PMID: 19280675) Pediatr Blood Cancer. 2019 Jul;66(7):e27660. (PMID: 30756484) Clin Chem Lab Med. 2000 Dec;38(12):1277-81. (PMID: 11205693) Int J Biol Macromol. 2019 Jul 1;132:844-851. (PMID: 30936009) Protein Sci. 2006 May;15(5):1093-105. (PMID: 16597834) Mediators Inflamm. 2009;2009:405016. (PMID: 20204172) Nanomedicine. 2012 Jan;8(1):71-80. (PMID: 21703363) Clin Chim Acta. 2008 Apr;390(1-2):1-11. (PMID: 18243141) World J Gastroenterol. 2014 Mar 7;20(9):2279-303. (PMID: 24605027) Nutrients. 2022 Feb 28;14(5):. (PMID: 35268000) J Food Biochem. 2021 Jan;45(1):e13579. (PMID: 33300136) PLoS One. 2015 Aug 19;10(8):e0135814. (PMID: 26288313) Mutat Res. 1999 Apr 6;440(2):181-8. (PMID: 10209341) Phytother Res. 2015 Mar;29(3):339-50. (PMID: 25572840) BMC Cancer. 2013 Dec 13;13:600. (PMID: 24330704) Pharmaceuticals (Basel). 2022 Apr 25;15(5):. (PMID: 35631354) Asian Pac J Cancer Prev. 2012;13(12):6295-8. (PMID: 23464448) J Ethnopharmacol. 2010 May 4;129(1):131-4. (PMID: 20307641) Environ Sci Pollut Res Int. 2020 Mar;27(9):9236-9246. (PMID: 31916166) Saudi J Biol Sci. 2021 May;28(5):3117-3125. (PMID: 34012333) Int J Health Sci (Qassim). 2018 May-Jun;12(3):88-93. (PMID: 29896077) Evid Based Complement Alternat Med. 2015;2015:948737. (PMID: 25713595) CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. (PMID: 20874701) Tumour Biol. 2017 Mar;39(3):1010428317695923. (PMID: 28347231) Oxid Med Cell Longev. 2013;2013:316523. (PMID: 23983897) Mol Cancer. 2019 Mar 30;18(1):63. (PMID: 30927923) Exp Toxicol Pathol. 2013 Mar;65(3):235-42. (PMID: 21920724) Mov Disord Clin Pract. 2020 Dec 29;8(2):193-207. (PMID: 33553488) Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):357-68. (PMID: 12220549) Indian J Exp Biol. 2010 Nov;48(11):1157-60. (PMID: 21117458) Cancer Res. 1967 Jun;27(6):1058-65. (PMID: 6027198) J Public Health Afr. 2018 Dec 21;9(3):841. (PMID: 30854178) Chronobiol Int. 1999 Mar;16(2):185-97. (PMID: 10219490) J Am Coll Nutr. 2021 Jan;40(1):70-85. (PMID: 32191153) J Intensive Care Med. 2007 Jul-Aug;22(4):187-93. (PMID: 17712054) Biomed Pharmacother. 2017 Jul;91:1006-1016. (PMID: 28525943) J Immunol. 1996 Jul 1;157(1):160-9. (PMID: 8683110) Curr Hypertens Rev. 2015;11(2):132-42. (PMID: 26022210) Nat Rev Immunol. 2005 Oct;5(10):749-59. (PMID: 16175180) Sci Rep. 2021 Aug 26;11(1):17248. (PMID: 34446789) Nat Rev Drug Discov. 2006 Sep;5(9):741-54. (PMID: 16915232) Trends Endocrinol Metab. 1995 Mar;6(2):37-42. (PMID: 18406681) Bioessays. 2004 May;26(5):533-42. (PMID: 15112233) Biol Psychiatry. 1998 Mar 1;43(5):315-9. (PMID: 9513745) Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun;154(2):103-16. (PMID: 20668491) Anticancer Agents Med Chem. 2019;19(1):101-111. (PMID: 30582485) Biomed Pharmacother. 2005 May;59(4):139-42. (PMID: 15862706) Tumour Biol. 2014 Apr;35(4):3391-403. (PMID: 24292954) Steroids. 2019 Dec;152:108485. (PMID: 31491446) Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201) J Ethnopharmacol. 2008 Mar 28;116(3):439-46. (PMID: 18249514) Asian Pac J Cancer Prev. 2014;15(20):8571-6. (PMID: 25374169) J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576) Cancer Lett. 2000 Apr 14;151(2):119-25. (PMID: 10738105) Pharmacol Res. 2015 Dec;102:1-11. (PMID: 26361726) Sci Rep. 2021 Apr 6;11(1):7542. (PMID: 33824353) Indian J Med Res. 2007 Apr;125(4):511-22. (PMID: 17598937) Cancers (Basel). 2019 Nov 01;11(11):. (PMID: 31683891) Food Chem Toxicol. 2011 Jun;49(6):1270-5. (PMID: 21385597) Pak J Pharm Sci. 2010 Jan;23(1):21-8. (PMID: 20067862) Brain Inj. 2015;29(11):1259-72. (PMID: 26274493) Am Heart J. 2009 Oct;158(4):659-66. (PMID: 19781428) Semin Oncol. 2010 Aug;37(4):327-38. (PMID: 20816503) J Oral Sci. 2014 Jun;56(2):135-42. (PMID: 24930750) Food Chem Toxicol. 2014 Oct;72:20-9. (PMID: 25010452) Acta Pharmacol Sin. 2004 Aug;25(8):1070-6. (PMID: 15301742) J Ethnopharmacol. 2004 Feb;90(2-3):185-9. (PMID: 15013179) Environ Sci Pollut Res Int. 2021 Aug;28(32):44226-44238. (PMID: 33851294) Sci Rep. 2020 Oct 21;10(1):17883. (PMID: 33087779) Biomedicines. 2021 Jul 31;9(8):. (PMID: 34440136) Environ Toxicol. 2020 Apr;35(4):528-537. (PMID: 31821727) Environ Sci Pollut Res Int. 2020 Sep;27(27):33723-33731. (PMID: 32529628) Biomed Pharmacother. 2018 Dec;108:457-466. (PMID: 30241049) Asian Pac J Cancer Prev. 2011;12(12):3221-8. (PMID: 22471457) Anticancer Agents Med Chem. 2020;20(18):2246-2266. (PMID: 32723257) Int J Biol Macromol. 2018 Feb;107(Pt B):1936-1944. (PMID: 29037871) Cancer. 2021 Aug 15;127(16):3029-3030. (PMID: 34086348) Pak J Pharm Sci. 2020 Jan;33(1(Supplementary)):393-401. (PMID: 32122873) Life Sci. 2006 Apr 25;78(22):2650-3. (PMID: 16307762) Nat Rev Cancer. 2005 Oct;5(10):796-806. (PMID: 16195751) Nat Commun. 2013;4:1758. (PMID: 23612299) Sci Rep. 2017 Mar 17;7:44822. (PMID: 28303957) |
| معلومات مُعتمدة: | PNURSP2022R74 Princess Nourah Bint Abdulrahman University |
| فهرسة مساهمة: | Keywords: Antioxidants; Cytokines; Ehrlich ascites carcinoma; Kidney; Liver; Moringa olifera oil extract |
| المشرفين على المادة: | 0 (Antioxidants) 9IKM0I5T1E (Quercetin) 0 (Plant Extracts) 0 (Anti-Inflammatory Agents) 0 (Plant Oils) |
| تواريخ الأحداث: | Date Created: 20231215 Date Completed: 20231216 Latest Revision: 20231216 |
| رمز التحديث: | 20231217 |
| مُعرف محوري في PubMed: | PMC10720142 |
| DOI: | 10.1186/s12906-023-04279-z |
| PMID: | 38098043 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!